Key Documents

View All Documentation

Y0001442

N-[(cis-4-Isopropylcyclohexyl)carbonyl]-D-phenylalanine

Name: <I>N</I>-[(<I>cis</I>-4-Isopropylcyclohexyl)carbonyl]-<SC>D</SC>-phenylalanine
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

N-[[cis-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanine

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₁₉H₂₇NO₃

CAS Number:

105816-06-6

Molecular Weight:

317.42

NACRES:

NA.24

UNSPSC Code:

41116107

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

grade

pharmaceutical primary standard

API family

nateglinide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

Description

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

N-[(cis-4-Isopropylcyclohexyl)carbonyl]-ᴅ-phenylalanine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Improved post-prandial ghrelin response by nateglinide or acarbose therapy contributes to glucose stability in Type 2 diabetic patients.

F Zheng et al.

Journal of endocrinological investigation, 36(7), 489-496 (2013-01-18)

Recent studies highlight an important role of ghrelin in glucose homeostasis, while the association between ghrelin regulation and glucose fluctuation is unclear. We compared the effects of two postprandial hypoglycemic agents on ghrelin response and determined the contribution of ghrelin

Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.

Ranee Chatterjee et al.

American journal of hypertension, 26(6), 723-726 (2013-02-19)

Low and low-normal serum potassium is associated with an increased risk of diabetes. We hypothesized that the protective effect of valsartan on diabetes risk could be mediated by its effect of raising serum potassium. We analyzed data from the Nateglinide

Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes.

Jian Zhou et al.

Diabetes technology & therapeutics, 15(6), 481-488 (2013-05-02)

Recent studies have identified postprandial glycemic excursions as risk factors for diabetes complications. This study aimed to compare the effects of nateglinide and acarbose treatments on postprandial glycemic excursions in Chinese subjects with type 2 diabetes. This was a multicenter

View All Related Papers

Global Trade Item Number

SKU	GTIN
Y0001442	04061833807842